Pimozide


Generic Medicine Info
Administration
May be taken with or without food.
Contraindications
Prolonged QT interval or family history of congenital long QT syndrome, history of cardiac arrhythmias, severe toxic CNS depression, comatose states, known uncorrected hypokalaemia or hypomagnesaemia; treatment of simple tics or tics other than those associated with Tourette's syndrome. Concomitant use with QTc-prolonging agents, SSRIs, CYP3A4 and strong CYP2D6 inhibitors; drugs that may cause motor and phonic tics (e.g. pemoline, methylphenidate, amphetamines) until it is determined if these drugs or Tourette disorder are causing tics.
Special Precautions
Patient with CV disease, history of seizures or other conditions that may lower seizure threshold (e.g. head trauma, brain damage, alcohol withdrawal); thyrotoxicosis, phaeochromocytoma, diabetes, decreased gastrointestinal motility, paralytic ileus, urinary retention, benign prostatic hypertrophy, xerostomia, or visual problems; blood dyscrasia, Parkinson's disease. Patients subjected to conditions that may elevate core body temperature (e.g. strenuous exercise, heat exposure, dehydration). Avoid abrupt withdrawal. Renal and hepatic impairment. Children and elderly. Pregnancy and lactation. CYP2D6 intermediate and poor metabolisers. Patient Counselling This drug may cause sedation and impaired alertness, if affected, do not drive or operate machinery. Monitoring Parameters Perform CYP2D6 genotyping or phenotyping at baseline. Monitor ECG at baseline and periodically thereafter especially during dose adjustments; CBC frequently during the 1st few months in at risk patients and as clinically indicated; cardiac function, electrolytes (e.g. serum K) Perform ocular examination yearly.
Adverse Reactions
Significant: Extrapyramidal symptoms including acute dystonic reactions, akathisia, pseudoparkinsonism, tardive dyskinesia; venous thromboembolism, grand mal convulsions, anticholinergic effects (e.g. constipation, xerostomia, blurred vision, urinary retention), CNS depression, oesophageal dysmotility or aspiration, hyperprolactinaemia, impaired core body temperature regulation. Eye disorders: Decreased accommodation, visual disturbance. Gastrointestinal disorders: Nausea, vomiting, diarrhoea, salivary hypersecretion, constipation, dry mouth. General disorders and administration site conditions: Hyperhidrosis, extreme exhaustion. Investigations: Weight increased. Metabolism and nutrition disorders: Anorexia, hyperglycaemia, hyponatraemia. Musculoskeletal and connective tissue disorders: Muscle spasm, muscle rigidity. Nervous system disorders: Dizziness, somnolence, headache, tremor, akinesia. Psychiatric disorders: Depression, insomnia, agitation, restlessness. Renal and urinary disorders: Nocturia, urinary frequency. Reproductive system and breast disorders: Erectile dysfunction, galactorrhoea, gynaecomastia, amenorrhoea, decreased libido. Skin and subcutaneous tissue disorders: Sebaceous gland overactivity, rash, pruritus.
Potentially Fatal: Neuroleptic malignant syndrome (NMS), altered cardiac conduction (e.g. QT interval prolongation, torsades de pointes, arrhythmias, ventricular tachycardia and fibrillation), blood dyscrasia (e.g. leucopenia, neutropenia, agranulocytosis).
Drug Interactions
Increased CNS depression produced by other CNS depressants (e.g. hypnotics, sedatives, strong analgesics). May impair the anti-Parkinson effects of levodopa. Increased risk of extrapyramidal effects with anti-emetics (e.g. metoclopramide). Increased risk of CNS toxicity with sibutramine. Enhanced hypotensive effect with Ca channel blockers. May cause electrolyte imbalance with diuretics (especially those causing hypokalaemia).
CIMS Class
Antipsychotics
ATC Classification
N05AG02 - pimozide ; Belongs to the class of diphenylbutylpiperidine derivatives antipsychotics.
Disclaimer: This information is independently developed by CIMS based on pimozide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in